Navigation Links
Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
Date:2/13/2013

MENLO PARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on neurodegenerative diseases, announced today that it has initiated the GMP manufacturing process for CNS-102 following its recent pre-IND meeting with the Food and Drug Administration (FDA).  CNS-102 is being developed initially to treat amyotrophic lateral sclerosis (ALS).

In its meeting with the FDA, Coyote was advised to apply for Fast Track designation when it submits its Investigational New Drug (IND) application for CNS-102 for the treatment of ALS.  Coyote expects to file its IND in the fourth quarter of 2013 and commence a Phase 1 clinical study of CNS-102 in early 2014.

"Initiating the GMP manufacturing process for CNS-102 signals the first step in our clinical development program for ALS and follows a successful meeting with the FDA in which we were advised to seek Fast Track designation for CNS-102 in ALS," commented Hiroaki Serizawa , Ph.D., president, CEO & co-founder of Coyote Pharmaceuticals.  "Given that Fast Track designation is not typically discussed until Phase 2 data is produced, we view the FDA's position as very encouraging for our technology and strategy of targeting heat shock protein induction as a potential treatment for ALS."

According to the FDA, Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need.  The purpose is to get important new drugs to the patient earlier.  Most drugs eligible for Fast Track designation are likely to be considered appropriate to receive a Priority Review.  A Priority Review means that the time it takes FDA to review a new drug application is reduced.  The goal for completing a Priority Review is six months.

About Coyote Pharmaceuticals:
Coyote Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on treating neurodegenerative diseases through the mitigation of protein misfolding and pathological protein aggregation.  The company's lead drug candidate, CNS-102, is being developed initially to treat amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).  The orally bioavailable small molecule therapeutic is designed to activate gene expression of a family of proteins – known as heat shock proteins – which have evolved to regulate the folding and intracellular transport of other proteins. Heat shock proteins are capable of preventing and repairing the pathophysiological aggregation of several proteins that have been implicated in the etiology of ALS and AD.  For more information on Coyote visit http://www.coyotepharma.com.

For Media & Investors:
Jason Rando / Joshua Drumm , Ph.D.
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jrando@tiberend.com 
jdrumm@tiberend.com


'/>"/>
SOURCE Coyote Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
2. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
3. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
4. Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
5. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
6. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
7. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
9. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
10. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
11. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 Summary Provides ... partnering deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605668-summary/view-report.html Description The Global Non-Small Cell Lung ... understanding and access to partnering deals and agreements entered ... - Trends in partnering deals - Top deals ...
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... was valued at $3,453 million in 2015 and is projected to reach $5,334 million ... implants segment held nearly two-fifths of the total market in 2015. ... ... ...
(Date:2/22/2017)... Feb. 22, 2017   Protein Sciences Corporation , ... Flublok® Influenza Vaccine , announced today that they donated ... Vaccine Introduction (PIVI) and the Mongolian Ministry of Health ... the flu.  The doses of Flublok have been distributed ... for health care workers, pregnant women, and ...
Breaking Medicine Technology:
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... exam and eligibility requirements effective with the April 2017 testing period. NACCM, a ... , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure that ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving ... fewer trips the emergency room, fewer hospital admissions, and better blood pressure and ... Care® (AJMC®) finds. The study can be found here . , The ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 ... doses or not filling a prescription because they could not afford to pay ... getting medications were 30-60%*. At the same time, hospitals, pharmacies, manufacturers ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing ... ophthalmologist, Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in ... liability, premise liability and other personal injury cases. These injuries have a major ...
Breaking Medicine News(10 mins):